Use of tight junction antagonists to treat inflammatory bowl disease
The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents.
1. A method for treating Inflammatory Bowel Disease (IBD) in a patient in need thereof, the method comprising: administering a composition comprising a peptide having the amino acid sequence GGVLVQPG (SEQ ID NO:15) to the duodenum of the patient, wherein the peptide is being administered in a delayed release composition that is stable in gastric fluid and unstable in intestinal fluid so as to release an effective amount of the peptide in the duodenum of the patient.
2. The method of claim 1 , wherein the patient has Crohn's Disease.
3. The method of claim 1 , wherein the peptide is further administered to the jejunum of the patient.
4. The method of claim 1 , wherein at least 70% by weight of the peptide is released by the composition in from 5 to 90 minutes of exposure to simulated intestinal fluid having a pH of greater than 5.
5. The method of claim 1 , wherein at least 70% by weight of the peptide is released by the composition by about 60 minutes of exposure to simulated intestinal fluid having a pH of greater than 5.
6. The method of claim 1 , further comprising, administering an active agent selected from an aminosalicylate, corticosteroid, immunomodulator, or antibiotic.
7. The method of claim 6 , wherein the aminosalicylate is 5-aminosalicyclic acid (5-ASA).
8. The method of claim 1 , wherein the peptide is administered one or more times per day.
9. The method of claim 8 , wherein the peptide is administered chronically.
10. The method of claim 1 , wherein the subject is not undergoing an acute Inflammatory Bowel Disease (IBD) attack at the time the peptide is administered.
11. The method of claim 1 , wherein the subject is undergoing an acute attack of Inflammatory Bowel Disease (IBD) at the time the peptide is administered.
12. The method of claim 1 , wherein the patient is human.
13. The method of claim 1 , wherein the patient is a dog.
14. A method for treating chronic Inflammatory Bowel Disease (IBD) in a patient in need thereof, the method comprising: administering a composition comprising a peptide having the amino acid sequence GGVLVQPG (SEQ ID NO: 15) in an effective amount to the patient one or more times per day for a plurality of days, wherein the peptide is being administered in a delayed release composition that is stable in gastric fluid and unstable in intestinal fluid so as to release the peptide in the duodenum and jejunum of the patient.